Amsterdam, the Netherlands, 17 June 2015. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of Neuravi Ltd., a private Irish company commercializi [...]
Breda, The Netherlands / Ghent, Belgium, June 17, 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies [...]
Simultaneous Detection of Infection and Antibiotic Resistance
Bath, UK, 11 June 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, [...]
Utrecht, The Netherlands, June 1, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of [...]
Safe dose established for next stage studies
Biological activity observed in MET-amplified cancer patient
Breda, The Netherlands / Ghent, Belgium, May 29, 2015 - arGEN-X N.V. (Euronext Brussels [...]
Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark, May 21, 2015 – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therap [...]
Utrecht, The Netherlands, May 20, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, and Selexis SA, a serial innovation company with proven technologie [...]
LSP’s Clemens van Blitterswijk welcomes the King at MERLN
http://www.maastrichtuniversity.nl/web/Main/Sitewide/News1/KingVisitsUMInstituteMERLN1.htm
[...]
Europe Editor
On the strength of a 29-patient Phase II clinical study that generated a strong newsflow about a potential treatment for stroke rehabilitation, Nexstim (Helsinki, Finland) CEO Janne Huhtala took his [...]
--Further Posters to be Presented on Translational Data for CD33/CD3-TandAb Program--
Heidelberg, Germany, May 13, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on d [...]
Amsterdam, the Netherlands, 17 June 2015. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of Neuravi Ltd., a private Irish company commercializi [...]
Breda, The Netherlands / Ghent, Belgium, June 17, 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies [...]
Simultaneous Detection of Infection and Antibiotic Resistance
Bath, UK, 11 June 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, [...]
Utrecht, The Netherlands, June 1, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as President of [...]
Safe dose established for next stage studies
Biological activity observed in MET-amplified cancer patient
Breda, The Netherlands / Ghent, Belgium, May 29, 2015 - arGEN-X N.V. (Euronext Brussels [...]
Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark, May 21, 2015 – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therap [...]
Utrecht, The Netherlands, May 20, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, and Selexis SA, a serial innovation company with proven technologie [...]
LSP’s Clemens van Blitterswijk welcomes the King at MERLN
http://www.maastrichtuniversity.nl/web/Main/Sitewide/News1/KingVisitsUMInstituteMERLN1.htm
[...]
Europe Editor
On the strength of a 29-patient Phase II clinical study that generated a strong newsflow about a potential treatment for stroke rehabilitation, Nexstim (Helsinki, Finland) CEO Janne Huhtala took his [...]
--Further Posters to be Presented on Translational Data for CD33/CD3-TandAb Program--
Heidelberg, Germany, May 13, 2015 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on d [...]
Follow us
